Teva Pharmaceutical Industries (TEVA) Divestments (2020 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Divestments for 7 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Divestments fell 55.56% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $54.0 million (down 20.59% YoY), and the FY2025 full-year result was $34.0 million, down 20.93% from the prior year.
• Divestments declined to $4.0 million in Q2 2026 per TEVA's latest filing, from $42.0 million in the prior quarter.
• Across five years, Divestments topped out at $56.0 million in Q2 2023 and bottomed at $1.0 million in Q2 2024.
• Historically, Divestments has averaged $17.3 million across 5 years, with a median of $10.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Divestments plunged 98.21% in 2024, then soared 800.0% in 2025.
• Over 5 years, Divestments stood at $23.0 million in 2022, then slumped by 56.52% to $10.0 million in 2023, then plunged by 60.0% to $4.0 million in 2024, then jumped by 100.0% to $8.0 million in 2025, then plunged by 50.0% to $4.0 million in 2026.
• According to Business Quant data, Divestments over the past three periods registered $4.0 million, $42.0 million, and $8.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.